SOPHiA Expands Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing

SOPHiA GENETICS and AstraZeneca are expanding their collaboration to accelerate global liquid biopsy testing deployment. The partnership will extend MSK-ACCESS powered with SOPHiA DDM to 30 clinical institutions worldwide in 2025.

Key highlights:The liquid biopsy test detects genomic alterations from a single blood draw using advanced algorithms to analyze circulating tumor DNA
This testing method offers advantages when traditional tissue biopsies are impractical due to cost, time, or invasiveness
New data presented at AACR shows consistent accuracy across different laboratory settings

The expanded rollout supports AstraZeneca's real-world evidence initiatives and aims to validate decentralized liquid biopsy testing's clinical impact. The collaboration addresses a major industry challenge, as site-to-site result consistency has historically limited liquid biopsy adoption. Recent study results confirm the test maintains high analytical performance across multiple centers, matching the original standards set at Memorial Sloan Kettering Cancer Center.

https://www.stocktitan.net/news/SOPH/sop-hi-a-genetics-announces-expanded-collaboration-with-astra-zeneca-72zuplxffu5s.html